Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAL: Bortezomib vs Thalidomide in Myeloma with Renal Failure
NCT02424851Phase 2Completed
- Sponsor
- Oxford University Hospitals
- Start
- Nov 2014
- Primary completion
- Apr 2020
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, thalidomide in multiple myeloma (MM), sponsored by Oxford University Hospitals. Started Nov 2014; status: completed.
02
Drugs
bortezomibthalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02424851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02424851.